Humacyte Stock Holdings Turnover

HUMAW Stock

USD 1.74 0.49 39.20%

Humacyte fundamentals help investors to digest information that contributes to Humacyte's financial success or failures. It also enables traders to predict the movement of Humacyte Stock. The fundamental analysis module provides a way to measure Humacyte's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Humacyte stock.

Short Long Term Debt Total Total Assets

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Humacyte Company Holdings Turnover Analysis

Humacyte's Holding Turnover is calculated by adding up all the transactions for the year, dividing it by 2 and then dividing it again by the total fund holdings. Holding Turnover is the rate at which funds or ETFs replace their investment holdings on an annual basis. In other words it measures how quickly a fund turns over its holdings during the fiscal year.

Holding Turnover

Year Cash Flow

Net Asset

100

More About Holdings Turnover | All Equity Analysis

Humacyte Holdings Turnover Driver Correlations

Understanding the fundamental principles of building solid financial models for Humacyte is extremely important. It helps to project a fair market value of Humacyte Stock properly, considering its historical fundamentals such as Holdings Turnover. Since Humacyte's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Humacyte's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Humacyte's interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Total Liab	Total Current Assets	Common Stock	Net Tangible Assets	Long Term Debt	Capital Surpluse	Net Invested Capital	Long Term Investments	Short Long Term Debt	Capital Stock	Net Working Capital	Short Term Debt	Current Deferred Revenue
Total Assets		0.49	-0.87	-0.11	-0.45	-0.13	-0.23	0.97	0.75	0.0	0.34	0.0	0.55	0.0	0.41	0.22	0.81	-0.05	-0.04
Total Stockholder Equity	0.49		-0.56	0.37	0.05	0.55	-0.96	0.39	0.12	0.22	-0.11	0.22	-0.06	0.22	-0.07	0.08	0.02	-0.02	0.14
Net Debt	-0.87	-0.56		-0.26	0.51	-0.13	0.3	-0.83	-0.76	-0.46	-0.1	-0.46	-0.31	-0.46	-0.25	-0.26	-0.6	0.13	-0.24
Retained Earnings	-0.11	0.37	-0.26		-0.34	0.91	-0.39	-0.29	-0.25	0.86	-0.89	0.86	-0.82	0.86	-0.81	-0.19	-0.59	-0.38	0.87
Accounts Payable	-0.45	0.05	0.51	-0.34		-0.05	-0.22	-0.37	-0.54	-0.44	0.35	-0.44	0.0	-0.44	0.19	-0.43	-0.31	-0.17	-0.28
Net Receivables	-0.13	0.55	-0.13	0.91	-0.05		-0.62	-0.33	-0.49	0.61	-0.84	0.61	-0.85	0.61	-0.83	-0.41	-0.67	-0.47	0.8
Total Liab	-0.23	-0.96	0.3	-0.39	-0.22	-0.62		-0.12	0.14	-0.14	0.21	-0.14	0.21	-0.14	0.19	0.0	0.23	-0.02	-0.11
Total Current Assets	0.97	0.39	-0.83	-0.29	-0.37	-0.33	-0.12		0.84	-0.09	0.53	-0.09	0.72	-0.09	0.61	0.32	0.91	0.07	-0.22
Common Stock	0.75	0.12	-0.76	-0.25	-0.54	-0.49	0.14	0.84		0.14	0.5	0.14	0.74	0.14	0.67	0.69	0.85	0.38	-0.31
Net Tangible Assets	0.0	0.22	-0.46	0.86	-0.44	0.61	-0.14	-0.09	0.14		-0.62	1.0	-0.52	1.0	-0.46	0.1	-0.31	-0.23	0.72
Long Term Debt	0.34	-0.11	-0.1	-0.89	0.35	-0.84	0.21	0.53	0.5	-0.62		-0.62	0.93	-0.62	0.97	0.27	0.74	0.3	-0.79
Capital Surpluse	0.0	0.22	-0.46	0.86	-0.44	0.61	-0.14	-0.09	0.14	1.0	-0.62		-0.52	1.0	-0.46	0.1	-0.31	-0.23	0.72
Net Invested Capital	0.55	-0.06	-0.31	-0.82	0.0	-0.85	0.21	0.72	0.74	-0.52	0.93	-0.52		-0.52	0.96	0.5	0.9	0.45	-0.78
Long Term Investments	0.0	0.22	-0.46	0.86	-0.44	0.61	-0.14	-0.09	0.14	1.0	-0.62	1.0	-0.52		-0.46	0.1	-0.31	-0.23	0.72
Short Long Term Debt	0.41	-0.07	-0.25	-0.81	0.19	-0.83	0.19	0.61	0.67	-0.46	0.97	-0.46	0.96	-0.46		0.46	0.8	0.41	-0.78
Capital Stock	0.22	0.08	-0.26	-0.19	-0.43	-0.41	0.0	0.32	0.69	0.1	0.27	0.1	0.5	0.1	0.46		0.38	0.9	-0.55
Net Working Capital	0.81	0.02	-0.6	-0.59	-0.31	-0.67	0.23	0.91	0.85	-0.31	0.74	-0.31	0.9	-0.31	0.8	0.38		0.19	-0.46
Short Term Debt	-0.05	-0.02	0.13	-0.38	-0.17	-0.47	-0.02	0.07	0.38	-0.23	0.3	-0.23	0.45	-0.23	0.41	0.9	0.19		-0.75
Current Deferred Revenue	-0.04	0.14	-0.24	0.87	-0.28	0.8	-0.11	-0.22	-0.31	0.72	-0.79	0.72	-0.78	0.72	-0.78	-0.55	-0.46	-0.75

Click cells to compare fundamentals

Investor can think of Holding Turnover as a percentage of a fund's assets that have turned over in the past year. Typically, a high annual turnover ratio implies that fund managers made a lot of buying and selling. The higher the annual turnover, the higher the expense ratio for the fund.

Competition

Predict Humacyte

According to the company disclosure, Humacyte has a Holdings Turnover of 0.0%. This indicator is about the same for the Biotechnology average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).

Did you try this?

Run Stock Screener Now

Stock Screener

Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.

All Next

Launch Module

Humacyte Fundamentals

	Return On Equity	-8.51
	Return On Asset	-0.53
	Number Of Shares Shorted	703
	EBITDA	(96.46 M)
	Net Income	(110.78 M)
	Total Debt	58.11 M
	Book Value Per Share	(0.53) X
	Cash Flow From Operations	(73.31 M)
	Earnings Per Share	(3.16) X
	Number Of Employees	183
	Beta	1.47
	Total Asset	128.22 M
	Retained Earnings	(537.31 M)
	Working Capital	64.83 M
	Net Asset	128.22 M

About Humacyte Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Humacyte's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Humacyte using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Humacyte based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

Additional Tools for Humacyte Stock Analysis

When running Humacyte's price analysis, check to measure Humacyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Humacyte is operating at the current time. Most of Humacyte's value examination focuses on studying past and present price action to predict the probability of Humacyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Humacyte's price. Additionally, you may evaluate how the addition of Humacyte to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC